NDAOPHTHALMICGEL
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
8
Mechanism of Action
Pharmacologic Class:
Prostaglandin Analog
Clinical Trials (5)
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
Started Feb 2023
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Started Jun 2022
A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Jun 2020
37 enrolled
Open-Angle GlaucomaOcular Hypertension
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Started Mar 2019
455 enrolled
Open-Angle GlaucomaOcular Hypertension
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Started Feb 2019
515 enrolled
Open-Angle GlaucomaOcular Hypertension
Loss of Exclusivity
LOE Date
Jun 8, 2036
125 months away
Patent Expiry
Jun 8, 2036
Exclusivity Expiry
Sep 9, 2028
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10314780 | Jun 8, 2036 | Product | U-1295 |
Company
Thea Pharma
MA - Waltham